Tags : FTC

Elanco Receives the US FTC’s Approval for Acquisition of Bayer

Shots: Elanco has received the US FTC’s approval for its acquisition of Bayer Animal Health, representing the final antitrust clearance needed to complete the transaction, which continues track for closing at the beginning of August The FTC’s approval follows divestiture of global rights for Osurnia to treat otitis externa in dogs, US rights for Capstar […]Read More

Insights+ Key Biosimilars Events of February 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence providers are likely to adopt biosimilars “a reference product to biologics” possessing similar […]Read More

Danaher Receives S.Korean FTC’s Conditional Approval for its $21.4B GE

Shots: South Korea’s FTC has approved Danaher’s $21.4 billion acquisition of GE biopharma on condition that the companies will sell eight bioprocessing product assets addressing monopoly concerns The FTC’s approval follows EU’s conditional approval received in Dec 2019 after it agrees to sell five businesses to address worries about competition In Feb’2019, Danaher announced the […]Read More

The US FDA and FTC Sign Agreement to Support the

The partnership will address the false and misleading promotion about biosimilars within their respective authorities and prevent anti-competitive behavior. Additionally, the agencies will collaborate with participants from industry, academia and government agencies for discussing issues related to competition in the biologics market The agencies will collaboratively exchange the information for suitable practices in preventing the […]Read More

AbbVie to Divest Allergan’s Brazikumab and Zenpep (pancrelipase) to Gain

Shots: Allergan will divest its brazikumab to AstraZeneca including its global development and commercialization rights while Nestle to acquire complete ownership of Zenpep and will be acquiring Viokace as a part of the same transaction The divestiture of two therapies is in conjunction with the ongoing US FTC’s and EC’s approval. The transactions are expected […]Read More

Bristol-Myers Squibb to Divest Celgene’s Otezla (apremilast) to Gain the

Shots: BMS plans to divest Otezla to address US Federal Trade Commission concern to close pending Celgene acquisition for $74B more quickly In Jan’2019, BMS announced to acquire Celgene with its expected closing of the transaction in H2’19 or H1’20. The divestiture of Otezla will accelerate BMS post-closing deleveraging plans Otezla is a PDE4 inhibitor, […]Read More